A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEXAfter Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma

Trial Profile

A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEXAfter Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Anti-TA-MUC1 monoclonal antibody (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Glycotope
  • Most Recent Events

    • 15 Aug 2017 This study has been discontinued in Hungary as per Eudra.
    • 13 Aug 2017 This study has been discontinued in Germany as per Eudra.
    • 13 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top